The Clinical and Translational Science Institute (CTSI) has expanded its current board of directors to more fully reflect the campuswide community that it serves. New board members include deans from the schools of dentistry, nursing, and pharmacy, as well as other key campus leaders.
Neurologist S. Claiborne “Clay” Johnston, MD, PhD, associate vice chancellor of research and director of the Clinical and Translational Science Institute, speaks to a colleague at UCSF Medical Center.
“This expansion further ensures that CTSI is fully integrated with the larger campus,” said Clay Johnston, MD, PhD, director of CTSI and associate vice chancellor of research at UCSF. “And it makes us more accountable. Since CTSI’s efforts to accelerate translational research touch all sectors of the UCSF campus, we want the campus broadly represented at the table.”
New board members include:
- Joshua Adler, MD; chief medical officer, UCSF Medical Center and UCSF Benioff Children's Hospital
- Jeffrey Bluestone, PhD; UCSF Executive Vice Chancellor and Provost
- John Featherstone, MSc, PhD; dean, UCSF School of Dentistry
- Mary Anne Koda-Kimble, PharmD; dean, UCSF School of Pharmacy
- David Vlahov, RN, PhD, FAAN; dean, UCSF School of Nursing
Translating Science into Real-life Solutions
The CTSI, which works to accelerate the pace of translating science into real-life solutions for patients, received $112 million from the National Institutes of Health (NIH) to expand its work over the next five years. The UCSF CTSI is among 10 institutes nationwide to receive the renewed funding, in recognition of their successes during the first five years of the NIH’s Clinical and Translational Science Awards program.
Together, the institutes represent a $498 million renewed commitment on NIH’s part to expedite translational research nationwide. UCSF received the largest of the renewal grants and remains the country’s second-largest clinical and translational science institute in the U.S. Read more about the board on the CTSI website.